Illustrative stock photograph; it does not show the trial, its supplement, or its results. Photo: CDC / Unsplash.
A six-month trial found better blood-vessel function and lower systolic blood pressure with a multi-ingredient supplement. The results are preliminary, measure risk markers rather than heart attacks or longevity, and come with important commercial ties.
What changed
Researchers randomized 61 generally healthy adults over 40 to the supplement or a look-alike control; 43 completed both visits. Compared with control, the supplement group had a 2.9-percentage-point improvement in flow-mediated dilation, 1.18 m/s lower pulse-wave velocity, and 6.1 mmHg lower systolic blood pressure after six months. Blood lipids did not change.
How strong is the evidence?
Small human randomized trial. Double-blinding and a matched control strengthen the comparison. However, the sample was small, 18 participants did not complete both visits, and the outcomes were surrogate markers—not clinical events.
What remains uncertain
The study cannot show which of the many ingredients mattered, whether the changes last, or whether they prevent disease. NOVOS Labs supplied the products and a research grant; one author is a company employee, and another reported company research funding. Independent replication is needed.
Why it matters
The findings justify a larger trial, but they are not proof that a “longevity” supplement extends life or replaces established blood-pressure care. This brief does not recommend the tested product.
Sources
European Heart Journal Open study, published November 4, 2026. University of Surrey report, November 4, 2026.
